EGFR and non-small cell lung carcinoma: In the FLAURA III study, a double-blind phase III trial was performed in which 556 previously untreated patients with EGFR+ NSCLC were assigned to either the standard EGFR-TKI (gefitinib or erlotinib) or osimertinib.